Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Eurofins Ntd Llc |
RCV000729078 | SCV000856714 | pathogenic | not provided | 2018-08-16 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV000729078 | SCV001226178 | pathogenic | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg1057*) in the ABCB11 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ABCB11 are known to be pathogenic (PMID: 18395098, 20232290). This variant is present in population databases (rs72549397, gnomAD 0.008%). This premature translational stop signal has been observed in individual(s) with ABCB11-related disorders (PMID: 9806540, 27050426). ClinVar contains an entry for this variant (Variation ID: 6596). For these reasons, this variant has been classified as Pathogenic. |
| Baylor Genetics | RCV003472993 | SCV004210703 | pathogenic | Benign recurrent intrahepatic cholestasis type 2 | 2023-09-12 | criteria provided, single submitter | clinical testing | |
| OMIM | RCV000006975 | SCV000027171 | pathogenic | Progressive familial intrahepatic cholestasis type 2 | 1999-12-01 | no assertion criteria provided | literature only | |
| Natera, |
RCV000006975 | SCV002077888 | pathogenic | Progressive familial intrahepatic cholestasis type 2 | 2017-11-02 | no assertion criteria provided | clinical testing |